Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Portfolio Pulse from
Elevation Oncology has initiated dosing in a Phase 1 trial for its Claudin 18.2 ADC EO-3021, in combination with other drugs, targeting advanced gastric/GEJ cancer. Initial data is expected by late 2025 or early 2026. The company is also progressing with its HER3 ADC EO-1022, planning to present preclinical data in 2025 and file an IND application in 2026.
January 13, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elevation Oncology is advancing its ADC programs, with new trials for EO-3021 and EO-1022. Initial data for EO-3021 is expected by late 2025 or early 2026, and preclinical data for EO-1022 will be presented in 2025. These developments could enhance the company's position in cancer treatment.
The initiation of a Phase 1 trial and upcoming data releases for EO-3021 and EO-1022 indicate significant progress in Elevation Oncology's pipeline. These developments are likely to positively impact the company's stock as they address unmet medical needs in cancer treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100